Agreement - May 27, 2019
Affibody in agreement with 3P Biopharmaceuticals
The agreement with 3P Biopharmaceuticals (3P) covers process development and GMP manufacturing of Affibody’s ABY-035 drug. “Ensuring large scale high quality production of our ABY-035 drug is a natural next step in our evolution as a company with the ambition to have development, manufacturing, and commercialization expertise”, said David Bejker, CEO of Affibody. “The work […]
Agreement - March 20, 2019
Affibody announces co-development agreement with Alexion
Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody with an upfront payment of $25 million, with the potential for additional development- and sales-based milestones of up to $625 million and tiered low double-digit […]
Clinical Trials - May 12, 2017
Affibody to initiate phase II psoriasis trial
Affibody announces that it has decided to initiate Phase II development with ABY-035, which is the company’s proprietary psoriasis program. “This Affibody molecule, ABY-035, has been specifically designed to capture the unique aspects of the Affibody technology. It is a bi-specific construct with extraordinary affinity and confirmed antibody-like half-life. The initial results from our patient […]
Collaboration - December 5, 2014
Nanovector, Affibody to Collaborate
Norway’s Nordic Nanovector ASA and Sweden’s Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant, the project will combine Affibody’s proprietary platforms with Nordic Nanovector’s radioimmunotherapy technology. The project aims to provide documentation necessary […]
Acquisition - August 6, 2013
Affibody signs deal with Daiichi Sankyo
Stockholm-based Affibody AB announces a new collaboration with Japanese Daiichi Sankyo. The license agreement regards the use of Affibody’s proprietary Albumod platform, a platform designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life. The technology will be applied on one undisclosed molecule from Tokyo-based Daiichi Sankyo’s pipeline of proprietary protein therapeutics. Affibody […]
Biotech Award - May 22, 2013
Affibody wins SwedenBIO Award
Swedish biotech company Affibody received this year’s SwedenBIO Award during SwedenBIO’s annual conference on May 21 in Stockholm. The jury’s motivation was that “Affibody has on a long-term basis established a well-functioning and successful business model. Affibody has unique technology platform as the basis of the development of protein drugs and imaging products, adapted for […]
